China To Revise Law On Patent Abuse
This article was originally published in PharmAsia News
A draft of China's revised patent law will be submitted to the Standing Committee of the National People's Congress for review on Aug. 25. A key point of the revision is the restriction of patent rights abuse. The draft explains that in situations where public health is threatened by epidemics or infectious diseases, the patent administrative department under State Council can decide on imposing a mandatory licensing system for drugs to guarantee adequate supply. Bolar Exception rules are also included (PharmAsia News, July 22, 2008). If passed, the new law will benefit local firms, which are increasingly facing pharmaceutical MNC charges on patent infringement. (Click here for more - Chinese Language)
You may also be interested in...
A more conservative US Supreme Court may mean a less authoritative FDA, and drug pricing won’t get as much attention in the presidential campaign, which is a good thing.
The US HHS played defense on 20 September, pushing back on suggestions that secretary Alex Azar’s recent move to exert control over regulations by signing off on them was a power play aimed at the FDA. Meanwhile, former agency head Scott Gottlieb says it’s “the wrong move at the wrong time.”